Lecanemab

Blood-based biomarkers for treatment monitoring in Alzheimer’s disease

Ongoing concerns regarding lecanemab: efficacy & adverse events

ALZ-NET: examining novel approved treatments in the real-world

Development of Appropriate Use Recommendations for lecanemab

Prospects for Alzheimer’s disease monitoring and treatment in 2023

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310

Lecanemab: a review

Lecanemab: drawbacks to consider

Lecanemab vs aducanumab

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Highlights from CTAD 2022

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Lecanemab and what this means for the future treatment of Alzheimer’s disease

Future direction for anti-amyloid immunotherapies